Open-angle primary glaucoma (OAPG) is the most common form of Glaucoma in America occurring mainly above the age of 50. OAPG presents no symptoms and the disease often goes undetected developing slowly so that any damage to the optic nerve and loss of sight is gradual. Being painless means the patient does not realize that they are losing vision until the disease hits its later stage. By this time vision has been damaged and is irreversible.
Although vision loss in glaucoma is permanent, with early treatment damage can be reduced in some patients.
In OPAG there is a partial blockage within the trabecular meshwork. This creates a restriction on the drainage of aqueous humour. It is still not fully understood how the trabecular meshwork becomes blocked and does not drain well. If the drainage is defective the acqueous humour builds up, increasing the pressure within the eye.
This increased pressure damages the optic nerve along with nerve fibres that run towards it from the retina. At the back of the eye the retina holds the seeing cells. It is the damaged areas of the retina and nerve which result to permanent areas in loss of vision. This can even result in overall blindness.
Cataract eye drops is a remarkable product that helps prevent many eye disorders. Can-C eye drop is believed to have a positive effect on OPAG. The unique eye drop formula contains N-acetylcarnosine a natural chemical formula that consists of a blend of two amino acids (Alanine and Histidine). N-acetylcarnosine performs as a carrier of carnosine. Carnosine can be found naturally in foods and in human cells. It functions as a protector having anti-glycation and anti-oxidant properties. It is also able to reverse
Glycation, thus making it useful for tackling existing eye damage. N-acetylcarnosine transforms into pure carnosine eye drops once inside the eye.